Press release
Anti-CD20 Antibody Pipeline: 20+ Trailblazing Companies Powering the Future of Targeted Therapies | DelveInsight
Anti-CD20 Antibody Pipeline
DelveInsight's "Anti-CD20 Antibody Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Anti-CD20 Antibody market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
For emerging anti-CD20 antibody drugs, the anti-CD20 antibody pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Anti-CD20 Antibody Pipeline Report
• DelveInsight's anti-CD20 antibody Pipeline analysis depicts a robust space with 20+ active players working to develop 20+ pipeline drugs for anti-CD20 antibody treatment.
• The leading anti-CD20 antibody companies include TG Therapeutics, Roche, Genmab/Novartis, Biocad, Regeneron Pharmaceuticals, IGM Biosciences, Genentech, MENTRIK Biotech, Xencor, KindredBio, Boehringer Ingelheim, Bioxpress Therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec/Genentech, BioThera Solutions, and others are evaluating their lead assets to improve the Anti-CD20 Antibody treatment landscape.
• Key anti-CD20 antibody pipeline therapies in various stages of development include Ublituximab, Obinutuzumab, Ofatumumab, Glofitamab, Research programme: anti-CD20 monoclonal antibodies, Epcoritamab, Odronextamab, IGM-2323, BI 695500, Mosunetuzumab, AME-133v, XmAb13676, BXT 2336, 304, Ripertamab, DI Leu16 IL2, PF-05280586, Rituximab, BAT4306F, and others.
• In March 2025, Roche announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for GAZYVA®/GAZYVARO® (obinutuzumab) for treating lupus nephritis. The acceptance is based on positive Phase III REGENCY study results, which showed improved complete renal response when Gazyva was added to standard therapy.
• In February 2025, Regeneron announced that the FDA accepted the resubmitted Biologics License Application (BLA) for odronextamab to treat relapsed/refractory follicular lymphoma (FL) after two or more prior therapies. The FDA's target decision date is July 30, 2025.
• In March 2024, BeiGene announced that the FDA granted accelerated approval to BRUKINSA® (zanubrutinib), in combination with obinutuzumab, for treating adults with relapsed or refractory follicular lymphoma (FL) after two or more prior therapies.
• In August 2024, Indapta Therapeutics announced that the FDA cleared the IND for its Phase 1 trial of IDP-023, a g-natural killer (g-NK) cell therapy, for the treatment of progressive multiple sclerosis (MS).
Request a sample and discover the recent breakthroughs happening in the anti-CD20 antibody pipeline landscape @ https://www.delveinsight.com/report-store/anti-cd20-antibody-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Anti-CD20 Antibody Overview
CD20 is a non-glycosylated phosphoprotein, weighing 33-37 kDa, found on the surface of mature, undifferentiated B cells. Its expression begins at the pre-B-cell stage and continues until the cell differentiates into a plasma cell. Due to its consistent and high-level expression on malignant B cells, CD20 has become a key therapeutic target. Structurally, CD20 includes four hydrophobic transmembrane domains, one intracellular domain, and two extracellular loops (one large and one small), with both the N- and C-termini located within the cytoplasm.
The widespread presence of CD20 on transformed B cells underlies the development of anti-CD20 monoclonal antibodies (mAbs), which are used to deplete B cells. Initially designed to treat B cell malignancies such as non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), anti-CD20 therapies are now widely used for conditions characterized by high CD20 expression. These antibodies rank among the most effective therapies in both oncology and immune-related disorders.
Find out more about anti-CD20 antibody medication @ https://www.delveinsight.com/report-store/anti-cd20-antibody-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Anti-CD20 Antibody Treatment Analysis: Drug Profile
Ublituximab: TG Therapeutics
Ublituximab (TG-1101) is an investigational, glycoengineered anti-CD20 monoclonal antibody that targets a unique epitope on CD20-positive B cells. Upon binding, it initiates immune responses such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to B-cell destruction. TG Therapeutics has completed a rolling Biologics License Application (BLA) submission to the FDA for ublituximab as a treatment for chronic lymphocytic leukemia (CLL). The FDA has granted Fast Track designation to the ublituximab-umbralisib (U2) combination and Orphan Drug status for the same indication.
Glofitamab: Roche
Glofitamab (RO7082859, RG6026) is an investigational bispecific antibody that targets both CD20 on malignant B cells and CD3 on T cells, redirecting T cells to attack cancerous B cells. It is currently being evaluated in a Phase III trial comparing glofitamab + gemcitabine + oxaliplatin to rituximab + gemcitabine + oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Key Anti-CD20 Antibody Therapies and Companies
• Ublituximab: TG therapeutics
• Glofitamab: Roche
Learn more about the novel and emerging anti-CD20 antibody pipeline therapies @ https://www.delveinsight.com/report-store/anti-cd20-antibody-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Anti-CD20 Antibody Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Scope of the Anti-CD20 Antibody Pipeline Report
• Coverage: Global
• Key Anti-CD20 Antibody Companies: TG Therapeutics, Roche, Genmab/Novartis, Biocad, Regeneron Pharmaceuticals, IGM Biosciences, Genentech, MENTRIK Biotech, Xencor, KindredBio, Boehringer Ingelheim, Bioxpress Therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec/Genentech, BioThera Solutions, and others.
• Key Anti-CD20 Antibody Pipeline Therapies: Ublituximab, Obinutuzumab, Ofatumumab, Glofitamab, Research programme: anti-CD20 monoclonal antibodies, Epcoritamab, Odronextamab, IGM-2323, BI 695500, Mosunetuzumab, AME-133v, XmAb13676, BXT 2336, 304, Ripertamab, DI Leu16 IL2, PF-05280586, Rituximab, BAT4306F, and others.
Dive deep into rich insights for drugs used for anti-CD20 antibody treatment; visit @ https://www.delveinsight.com/report-store/anti-cd20-antibody-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Anti-CD20 Antibody Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Anti-CD20 Antibody Pipeline Therapeutics
6. Anti-CD20 Antibody Pipeline: Late-Stage Products (Phase III)
7. Anti-CD20 Antibody Pipeline: Late-Stage Products (Phase III)
8. Anti-CD20 Antibody Pipeline: Mid-Stage Products (Phase II)
9. Anti-CD20 Antibody Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anti-CD20 Antibody Pipeline: 20+ Trailblazing Companies Powering the Future of Targeted Therapies | DelveInsight here
News-ID: 3965890 • Views: …
More Releases from DelveInsight
Fuchs Dystrophy Pipeline Insight 2025: Emerging Cell and Gene Therapies Reshape …
DelveInsight's "Fuchs Dystrophy - Pipeline Insight, 2025" explores the dynamic pipeline for Fuchs Endothelial Corneal Dystrophy (FECD), a progressive eye disease characterized by corneal endothelial cell loss, leading to vision impairment and potential blindness. Current treatment relies on corneal transplantation, which is limited by donor shortages and surgical risks.
The pipeline showcases novel cell-based therapies, including endothelial cell injection and regenerative strategies designed to restore corneal transparency without the need for…
Polycystic 0vary Syndrome (PCOS) Pipeline Insight 2025: Innovative Hormonal and …
DelveInsight's "Polycystic 0vary Syndrome - Pipeline Insight, 2025" provides a thorough analysis of emerging therapeutic strategies for PCOS, a common endocrine disorder affecting reproductive-age women and associated with infertility, metabolic dysfunction, and psychological comorbidities. Current management relies heavily on lifestyle modification and symptom-targeted pharmacotherapy, leaving substantial unmet needs.
The pipeline features novel hormonal modulators, including selective androgen receptor antagonists, estrogen receptor modulators, and progesterone analogs, designed to restore hormonal balance…
Influenza A Virus H5N1 Subtype Pipeline Insight 2025: Next-Generation Vaccines a …
DelveInsight's "Influenza A Virus H5N1 Subtype - Pipeline Insight, 2025" presents a detailed overview of the therapeutic landscape for H5N1, a highly pathogenic avian influenza virus associated with severe respiratory disease and high mortality rates in humans. The pandemic potential of H5N1 continues to drive intense global R&D efforts.
The pipeline is rich with next-generation vaccines, including mRNA-based platforms, recombinant protein vaccines, and universal influenza vaccine candidates targeting conserved viral epitopes.…
Spasmodic Torticollis Pipeline Insight 2025: Novel Neurotoxins and Neuromodulati …
DelveInsight's "Spasmodic Torticollis - Pipeline Insight, 2025" provides a comprehensive analysis of the evolving treatment landscape for Spasmodic Torticollis (cervical dystonia), a chronic neurological disorder characterized by involuntary neck muscle contractions and abnormal head postures. Current standard therapies, including botulinum toxin injections, offer relief but remain limited by their variable duration of effect and the development of resistance.
The pipeline features next-generation botulinum toxin formulations, designed to extend therapeutic duration and…
More Releases for CD20
Anti-CD20 Monoclonal Antibodies (MAbs) Market Is Booming So Rapidly | Pfizer, Te …
The Global Anti-CD20 Monoclonal Antibodies (MAbs) Market Size is estimated at $12.8 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 10.2% to reach $30.7 Billion by 2034.
The latest study released on the Global Anti-CD20 Monoclonal Antibodies (MAbs) Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Anti-CD20 Monoclonal Antibodies (MAbs) market study covers significant research data and proofs to…
CD20 Antibody Market Forecast 2025-2034: Analysing Major Trends, Opportunities, …
Which drivers are expected to have the greatest impact on the over the cd20 antibody market's growth?
The increasing incidence of B-cell malignancies is also expected to propel the growth of the CD-20 antibody market. These malignancies, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, are on the rise due to factors like aging and genetic predisposition. CD20 antibodies, such as rituximab, target malignant B-cells to improve therapeutic outcomes. According to…
Anti-CD20 Antibody Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Anti-CD20 Antibody Pipeline Insight 2024" report provides comprehensive insights about 20+ Anti-CD20 Antibody companies and 20+ pipeline drugs in Anti-CD20 Antibody pipeline landscape. It covers the Anti-CD20 Antibody pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Anti-CD20 Antibody pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from…
Anti-CD20 Antibody Pipeline, FDA Approvals, Clinical Trials Developments and Com …
DelveInsight's, "Anti-CD20 Antibody Pipeline Insight" report provides comprehensive insights about 20+ Anti-CD20 Antibody companies and 20+ pipeline drugs in Anti-CD20 Antibody pipeline landscape. It covers the Anti-CD20 Antibody pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Anti-CD20 Antibody pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the…
CD20 Monoclonal Antibodies Market is growing at a healthy CAGR of 8.4% by 2028
The CD20 monoclonal antibodies market is estimated to gain market growth in the upcoming forecasted years. Data Bridge Market Research analyses the market is growing at a healthy CAGR of 8.4% in the above-mentioned research forecast period. The increasing R&D in generating potent CD20 monoclonal antibodies will drive the market.
The demand of CD20 monoclonal antibodies market has increased significantly because of advancements in technology, increasing demand of immunotherapy and fewer…
CD20 Monoclonal Antibodies Market is growing at a healthy CAGR of 8.4%
The CD20 monoclonal antibodies market is estimated to gain market growth in the upcoming forecasted years. Data Bridge Market Research analyses the market is growing at a healthy CAGR of 8.4% in the above-mentioned research forecast period. The increasing R&D in generating potent CD20 monoclonal antibodies will drive the market.
The demand of CD20 monoclonal antibodies market has increased significantly because of advancements in technology, increasing demand of immunotherapy and fewer…
